{"id":1071846,"date":"2017-04-22T16:44:39","date_gmt":"2017-04-22T20:44:39","guid":{"rendered":"http:\/\/www.antiagingmedicine.tv\/nanomedicine-award-2017-applications-are-now-open-cordis-news.php"},"modified":"2024-08-18T12:16:41","modified_gmt":"2024-08-18T16:16:41","slug":"nanomedicine-award-2017-applications-are-now-open-cordis-news","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nanomedicine-2\/nanomedicine-award-2017-applications-are-now-open-cordis-news.php","title":{"rendered":"Nanomedicine Award 2017: applications are now open! &#8211; Cordis News"},"content":{"rendered":"<p><p>  The European Technology Platform for Nanomedicine (ETPN) and the  EU-funded project ENATRANS, announce the launching of the 3rd  edition of the Nanomedicine Award, which aim to promote and  reward two excellent innovative nanomedicine-based solutions that  could bring significant benefits to patients, answering thereby  unmet medical needs. The winners in 2 categories will be  announced and rewarded during the BIO-Europe conference in Berlin  in November 2017. Apply Now!<\/p>\n<p>    Open to companies as well as to academic and private    researchers across the globe, candidates should:    - present totally new approaches based on Nanomedicine for the    diagnosis and\/or therapy of human diseases    - describe explicit and defined potential market.  <\/p>\n<p>    Applications will be assessed by a panel of highly-qualified    nanomedicine, pharma, medtech and investment specialists.  <\/p>\n<p>    The Award ceremony will take place during BIO-Europe 2017 in    Berlin (Germany), on 7 November 2017.  <\/p>\n<p>    Both winners will benefit from a full registration to    BIO-Europe 2017 including the participation in the partnering    event and a public presentation of the awarded projects. In    addition, they will be granted an individual session with the    experts of the Translation Advisory Board (TAB,    <a href=\"http:\/\/www.nanomedtab.eu\" rel=\"nofollow\">http:\/\/www.nanomedtab.eu<\/a>), a presentation slot during the ETPN Annual    Event 2018 as well as a 1-year free membership to the ETPN    (www.etpnanomedicine.eu).  <\/p>\n<p>    The Award is supported by the EBD Group, the leading partnering    firm for the global life science industry, and Nanobiotix, a    late clinical-stage nanomedicine company pioneering novel    approaches for the treatment of cancer.  <\/p>\n<p>    THE DEADLINE TO SUBMIT CANDIDATURES IS 15 AUGUST 2017. APPLY    ONLINE AT <a href=\"http:\/\/nanomedicine-award.com\/apply-now\/\" rel=\"nofollow\">http:\/\/nanomedicine-award.com\/apply-now\/<\/a>  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" href=\"http:\/\/cordis.europa.eu\/news\/rcn\/140455_en.html\" title=\"Nanomedicine Award 2017: applications are now open! - Cordis News\" rel=\"noopener\">Nanomedicine Award 2017: applications are now open! - Cordis News<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> The European Technology Platform for Nanomedicine (ETPN) and the EU-funded project ENATRANS, announce the launching of the 3rd edition of the Nanomedicine Award, which aim to promote and reward two excellent innovative nanomedicine-based solutions that could bring significant benefits to patients, answering thereby unmet medical needs.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nanomedicine-2\/nanomedicine-award-2017-applications-are-now-open-cordis-news.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":62,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577779],"tags":[],"class_list":["post-1071846","post","type-post","status-publish","format-standard","hentry","category-nanomedicine-2"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1071846"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/62"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1071846"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1071846\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1071846"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1071846"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1071846"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}